Navigation Links
Rheumatoid Arthritis Drugs Price Analysis and Strategies 2012-2016 & Forecasts to 2021 -Research and Markets
Date:2/28/2017

DUBLIN, Feb 28, 2017 /PRNewswire/ --


Research and Markets has announced the addition of the "Rheumatoid Arthritis Drugs Price Analysis and Strategies - 2016" report to their offering.

The latest research Rheumatoid Arthritis Drugs Price Analysis and Strategies - 2016, provides drug pricing data and benchmarks in the global Rheumatoid Arthritis market.

The research answers the following questions:

  • What are the key drugs marketed for Rheumatoid Arthritis and their clinical attributes? How are they positioned in the Global Rheumatoid Arthritis market?
  • What are the unit prices and annual treatment cost for Rheumatoid Arthritis therapies in different countries? What are the drug pricing trends and how are they expected to change in the future? How are the drug pricing and reimbursement landscape different by countries?
  • What are the unmet needs in the global Rheumatoid Arthritis drugs market? What would be the ideal pricing strategy for a new pipeline therapy for Rheumatoid Arthritis?

Research Scope:

  • Rheumatoid Arthritis Treatment Options - Identify key drugs marketed and prescribed for Rheumatoid Arthritis in the US, Germany, France, Italy, Spain, UK, Japan including trade name, molecule name, and company
  • Rheumatoid Arthritis Drugs Attributes - Find out the safety, efficacy, and risk benefit for key drugs marketed for Rheumatoid Arthritis
  • Market Positioning - Identify how drugs are clinically and commercially positioned in the global Rheumatoid Arthritis market
  • Rheumatoid Arthritis Drugs Price Analysis - Find out the annual therapy cost and unit price for key drugs marketed for Rheumatoid Arthritis in the US, Germany, France, Italy, Spain, UK, Japan. Find out how the price advanced from 2012 and forecast to 2021
  • Pricing & Reimbursement Landscape - Find out the pricing and reimbursement landscape in the US, Germany, France, Italy, Spain, UK, Japan
  • Rheumatoid Arthritis New Drug Pricing - Identify the effective pricing strategy for a new drug launch in the US, Germany, France, Italy, Spain, UK, Japan

This research will help executives

  • Identify clinical attributes of your competitor drugs
  • Find out how the marketed products for Rheumatoid Arthritis are clinically and commercially positioned
  • Understand the price of your competitor drugs by countries
  • Use Rheumatoid Arthritis drugs price data for market sizing, drug sales forecast, budgeting, competitive intelligence, HEOR, and reimbursement
  • Find out the pricing and reimbursement landscape by countries
  • Identify the unmet need in global Rheumatoid Arthritis market
  • Identify the effective pricing for a new drug

For more information about this report visit http://www.researchandmarkets.com/research/vjsw3w/rheumatoid

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com 

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716



To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rheumatoid-arthritis-drugs-price-analysis-and-strategies-2012-2016--forecasts-to-2021--research-and-markets-300414740.html


'/>"/>
SOURCE Research and Markets
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Rheumatoid Arthritis Patients are Moderately to Highly Satisfied with Their Current Drug Therapy, Rating Conventional DMARDs Highest on Ease of Use and Cost
2. Five-Year SIMPONI Data Reported In Treatment Of Signs And Symptoms Of Moderately To Severely Active Rheumatoid Arthritis
3. U.S. and European Rheumatologists Agree That a Therapys Induction of Remission is One of the Attributes That Most Influences Their Prescribing Decisions in Rheumatoid Arthritis
4. Pain Management Therapeutics Market to 2019 - Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline
5. MCOs Shifting Control Over Office-Administered Products from Medical to Pharmacy Benefit, Particularly Affecting Rheumatoid Arthritis Therapies
6. Isis Pharmaceuticals Reports Data From a Phase 2 Study of Isis-CRP Rx in Patients with Rheumatoid Arthritis
7. Surveyed U.S. Rheumatologists are Moderately Satisfied with Biologic Agents and Xeljanz to Treat Rheumatoid Arthritis
8. Hospira Shares Results From Two Open-label Extension Studies for Biosimilar Infliximab in Patients With Rheumatoid Arthritis or Ankylosing Spondylitis
9. Sanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial
10. Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis
11. Global Rheumatoid Arthritis Drugs Market 2014-2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2018)... ... October 16, 2018 , ... Censis Technologies announced today that ... tracking software company. Censis is the leader in the surgical inventory management space ... using their strong portfolio of solutions, including CensiTrac, LoanerLink, and ScopeTrac. , ...
(Date:10/16/2018)... ... ... Ripple Massage, Australia’s leading mobile massage company, has added to ... soaks to its packages. , “Ripple is much more than a mobile massage service,” ... all the pampering extras when they book a massage with us that can turn ...
(Date:10/16/2018)... ... 16, 2018 , ... The iaedp™ Foundation, recognized for excellence ... treatment providers who treat the full spectrum of eating disorder problems, will once ... track at Symposium 2019. The courses are regularly offered in a self-paced, ...
Breaking Medicine Technology:
(Date:10/18/2018)... NEW YORK (PRWEB) , ... October 18, 2018 ... ... services that include primary care, cancer and hematology, and a comprehensive Women’s Center, ... 80,000 square foot health complex at 5 Cuba Hill Road in Greenlawn, Suffolk ...
(Date:10/17/2018)... ... ... Power to Decide, the campaign to prevent unplanned pregnancy, announced the launch of ... from the HHS Office of Adolescent Health, Innovation Next is a unique accelerator program ... technology-enabled ideas. , This year, five new teams will be selected to participate in ...
(Date:10/16/2018)... (PRWEB) , ... October 16, 2018 , ... ... specializes in small business loans, equipment leasing, and franchise financing , is ... throughout the United States. Balboa Capital will structure and deliver custom-tailored financing programs ...
(Date:10/16/2018)... Va. (PRWEB) , ... October 16, 2018 , ... ... Oct. 23-25, 2018 – Bethesda, MD, http://www.fdanews.com/fdainspectionssummit , The 13th Annual ... last year’s Inspections Summit that it sometimes feels difficult to keep up. The ...
(Date:10/16/2018)... ... October 16, 2018 , ... ... research networking-technology company founded by patient-survivors, and The Avoca Group, Inc., a ... clinical trial execution process, today announced its mutual collaboration that will make ...
Breaking Medicine News(10 mins):